Over 77.6 billion in revenue! Will Baiyunshan be secure by 2025? Short-term pressures won't hinder long-term growth

Presented by | China Visit Network

Reviewed by | Li Xiaoyan

On the evening of March 20, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH/00874.HK) released its 2025 annual report. In a complex environment marked by policy shifts in the pharmaceutical industry and intensifying market competition, the company achieved full-year operating revenue of 77.656 billion yuan, up 3.55% year over year; attributable net profit to shareholders was 2.983 billion yuan, up 5.21% year over year, sustaining a steady growth momentum. At the same time, the company announced a cash dividend plan of 4.5 yuan (including tax) per 10 shares; the full-year dividend payout ratio reached 46.32%, rewarding shareholders with real cash. As a leading domestic pharmaceutical and healthcare industry group by scale, Baiyunshan, leveraging its end-to-end industrial chain layout, the advantages of its brand matrix, and strategic resolve, holds onto its core operating fundamentals during industry adjustment periods. Short-term fluctuations in financials and cash flow do not change the underlying color of long-term high-quality development.

In 2025, China’s pharmaceutical industry faces multiple challenges, including centralized procurement becoming normalized, healthcare reimbursement payment reforms, and adjustments to the structure of market demand. Many companies are trapped in a dilemma of revenue growth without profit growth and slowing profit growth rates. Baiyunshan withstood industry pressure, delivering synchronized growth in revenue and net profit, demonstrating the risk-resilience and operating tenacity of a large pharmaceutical group. In the reporting period, the company’s total profit was 3.69 billion yuan, up 2.28% year over year; return on weighted average net assets was 8.09%; return on invested capital was 6.12%. Key profitability indicators remained stable, and overall profitability quality was solid.

From a business-structure perspective, the pharmaceutical distribution segment became the key growth engine. Full-year revenue reached 56.983 billion yuan, up 6.21% year over year, accounting for over 73% of revenue and playing the role of a “stabilizing anchor.” Against the backdrop of continuously improving concentration in the pharmaceutical distribution industry and intensifying regional competition, Baiyunshan, relying on its improved distribution network, delivery system, and supply-chain integration capabilities, continued to expand market coverage and consolidate its leading position in South China and even nationwide pharmaceutical distribution. The steady growth of pharmaceutical distribution effectively offset some short-term pressure in certain industrial segments, supporting the company’s overall revenue to keep climbing.

On the shareholder-return front, Baiyunshan has consistently maintained the excellent tradition of high-percentage cash dividends. In 2025, the company plans to distribute cash dividends of about 732 million yuan. Combined with interim dividends, the total cash dividends for the full year will reach 1.382 billion yuan, accounting for 46.32% of attributable net profit. Since the company’s major asset restructuring in 2013, it has carried out 15 rounds of cash dividends in total, continuously creating stable returns for investors and demonstrating confidence in its development outlook and high regard for shareholders’ equity.

After years of deep cultivation, Baiyunshan has built an end-to-end industrial-chain ecosystem covering modern traditional Chinese medicine, chemical/pharmaceutical technology, natural beverages, pharmaceutical distribution, biological innovation, consumer healthcare, and medical services—forming a diversified business layout characterized by coordination across upstream and downstream activities and linkage among multiple segments. This layout has become the core advantage for the company to navigate through industry cycles. The group owns two national-level brands, “Baiyunshan” and “Wanglaoji.” It holds more than 3,000 trademarks of various types, including 10 well-known trademarks in China, 22 well-known trademarks in Guangdong Province, and 27 well-known trademarks in Guangzhou City. Its 13 member enterprises have been recognized as “China’s Time-Honored Brands,” and 16 are “Time-Honored Brands of Guangdong.” The brand heritage and market recognition are second to none among domestic pharmaceutical and healthcare companies.

In the pharmaceutical manufacturing (industry) sector, although the modern TCM, chemical/pharmaceutical technology, and natural beverage segments have experienced short-term revenue adjustments due to industry policy, market competition, and other factors, the company’s core product matrix remains solid. In the TCM segment, it relies on time-honored craftsmanship and classic product lines to maintain brand barriers in areas such as chronic-disease management and healthy-consumption. In the chemical/pharmaceutical segment, it follows the trend of centralized procurement policy, optimizing product structure and capacity layout to enhance the scale effect of winning bid products. In the natural beverage segment, centered on Wanglaoji, it continues to deepen the cooling-tea market, expand consumer scenarios, and consolidate its leading position in the industry. Short-term revenue volatility is a phased adjustment driven by the company’s proactive adaptation to policies, optimization of product structure, and focus on high–gross-margin products. Over the long term, the product strength and brand strength of the industrial segment still have strong potential for recovery.

Regarding innovation and strategic development, the company, centered on its strategy positioning in bio-pharmaceutical healthcare, steadily advances bio-innovation, research upgrades, and industrial integration. Although R&D expenses have changed year over year, the company always focuses on core directions such as modernization of TCM, the combination of generic/custom and innovative drugs, and R&D of biopharmaceuticals. Relying on its R&D platforms and collaboration between universities and research institutions and the industry, it has reserved a batch of in-development products with market potential. As innovation results are gradually converted, it will open new room for growth and drive a transformation of business from scale-driven to innovation-driven.

Annual report data show that some of the company’s financial indicators experienced phase-based fluctuations, drawing market attention. From an objective perspective, these fluctuations are mostly due to industry-common factors and short-term environmental impacts, not because the fundamentals of operations have deteriorated, and overall risk remains controllable.

In terms of earnings structure, in 2025 the company’s non-recurring net profit was 2.363 billion yuan, up 0.29% year over year. The growth rate lagged that of attributable net profit, mainly benefiting from a reasonable supplement of non-recurring gains. In the reporting period, non-recurring gains and losses totaled 620 million yuan, including asset disposals, government subsidies, and financial asset gains, among others. These gains are the normal result of the company activating existing assets and benefiting from supportive industrial policies, effectively adding to profit for the period. Against the backdrop of pressured profit margins in the industry, the relatively modest contribution of non-recurring gains to net profit reflects the company’s ability to operate assets and integrate resources, providing time and space for the transformation of its core businesses.

On cost and expense control, operating cost increased 4.12% year over year, slightly higher than the revenue growth rate, mainly due to cost rigidity effects brought by raw material price changes, supply-chain costs, and the expansion of the pharmaceutical distribution segment’s scale. Selling expenses and administrative expenses grew 3.69% and 4.20% year over year, respectively, roughly matching the revenue growth rate, and are considered normal investment for business expansion and operational management. Finance costs surged 635.66% year over year. The company clearly stated that this was caused by the decline in market interest rates leading to a sharp reduction in deposit interest income—not because interest expenses got out of control or debt risk increased. This factor is a phase-based impact resulting from the macro interest-rate environment and does not indicate a decline in the company’s financial management and control capability. As the interest-rate environment and funding-management strategies adjust, finance costs are expected to return to reasonable levels.

In terms of cash flow and operating efficiency, in 2025 net cash flow from operating activities was -0.232 billion yuan, turning from positive to negative year over year. This was mainly due to slower collection timing of payments from downstream customers and increased upstream procurement payments. This is also a common phenomenon for pharmaceutical distribution enterprises in an environment where industry receivable collection cycles are lengthening. The accounts receivable turnover rate and inventory turnover rate slowed slightly, reflecting short-term pressure on both cash collections and inventory management. However, the company has a robust asset scale and smooth financing channels, and overall the capital chain remains safe. At the same time, the company has strengthened targeted collections of accounts receivable, optimized inventory management, and improved supply-chain turnover efficiency. With adjustments to its operating strategy, operating cash flow is expected to gradually recover.

As a policy-sensitive industry, the pharmaceutical sector is continuously reshaping the industry landscape through normalized centralized procurement, healthcare reimbursement reforms, and supportive policies for innovative drugs. In its annual report, Baiyunshan candidly addresses policy risks, product-quality risks, R&D risks, and market risks, reflecting the responsibility and commitment of a mature enterprise. Facing industry changes, the company sticks to its main responsibilities and core businesses, responding to policy fluctuations with its end-to-end industrial-chain advantages; resisting market competition with brand value; and seizing development opportunities through innovation-led transformation.

Currently, China’s pharmaceutical industry is shifting from high-speed growth to high-quality development. Increased concentration, innovation-driven growth, and value returning to center have become core trends. As an industry leader, Baiyunshan has four core advantages: scale, brands, channels, and coordination across the industrial chain. It is also among the first tier in the industry in terms of policy adaptability, resource integration capability, and risk resilience. Short-term business adjustments and financial fluctuations are proactive adaptation by leading enterprises during industry transformation, not passive pressure.

In 2025, in the midst of industry changes, Baiyunshan kept the bottom line for steady and sound operations: both revenue and net profit increased, dividend returns were substantial, its end-to-end industrial-chain advantages remained solid, and brand value continued to lead. Although it faces challenges such as phase-based cash-flow pressure, a short-term rise in finance costs, and slower growth in some segments, these issues stem from industry commonalities and short-term factors. Risks are controllable, and recovery is achievable.

In the future, as the company continues to optimize its business structure, strengthen operational management, and accelerate innovation conversion, the scale advantage of pharmaceutical distribution, the brand advantage of pharmaceutical manufacturing, and the consumer advantage of the healthy-lifestyle/healthcare segment will further coordinate and be released. As a leading enterprise in China’s pharmaceutical and healthcare industry, Baiyunshan—backed by deep industrial accumulation, strong strategic resolve, and continued reform and innovation—will surely move forward steadily and far in the wave of high-quality development, creating greater value for investors, consumers, and society.

A massive amount of information and precise analysis—available on the Sina Finance app